BORTLIEVA (Bortezomib Injection IP 2 mg/Vial) is a targeted oncology injectable medication manufactured by Allieva Pharma Private Limited, specifically designed for the treatment of hematological malignancies such as multiple myeloma and mantle cell lymphoma. This scheduled drug is a reversible proteasome inhibitor that disrupts the 26S proteasome function, leading to the accumulation of misfolded proteins, inducing apoptosis in malignant plasma cells. BORTLIEVA is administered via intravenous or subcutaneous routes and is critical in both newly diagnosed and relapsed/refractory cases of multiple myeloma and relapsed mantle cell lymphoma. Each 2 mg vial is formulated for single-dose preparation to ensure dosage accuracy based on body surface area (1.3 mg/m² per dose). Given its potent mechanism and risk profile including peripheral neuropathy and thrombocytopenia, usage is strictly under physician supervision and requires prescription. Antiviral prophylaxis like acyclovir is recommended to mitigate herpes zoster reactivation risk during therapy. BORTLIEVA is made in India and available for bulk purchase from RADHAKRUSHNA MEDICALS with a minimum order quantity of 1 piece.

*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.